Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population
Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population
复制标题
中国汉族系统性硬化症人群自身抗体商业免疫分析的评价
DOI：
10.1016/j.cca.2019.01.020
复制
发表时间：
2019-04-01
影响因子：
5
通讯作者：
Li, Yongzhe
中科院分区：
文献类型：
--
作者：
Liu, Chenxi;Hou, Yong;Li, Yongzhe
目的：中国汉族系统性硬化症（SSc）患者自身抗体谱在不同种族间存在差异，但很少报道。本研究的目的是调查中国汉族SSc患者的自身抗体谱使用商业线免疫测定。方法：在从健康对照（n = 30）获得的血清样品中分析针对Ro-52、PDGFR、Ku、PM 75、PM 100、Th/To、NOR 90、Fib、RP 155、RP 11、CENP-B、CENP-A和Scl-70的自身抗体的流行率，SSc患者（n = 320）和非SSc结缔组织疾病患者（n = 100）使用Euroline系统性硬化症特征试剂盒。SSc患者抗RP 11的患病率增加（P = 0.032）、抗CENPB（P < 0.001）、抗CENPA（P = 0.001）和抗Scl-70（P < 0.001），但与非SSc CTD相比，抗Ro-52（P = 0.004）的患病率降低。此外，与HC相比，SSc患者抗Ro-52（P = 0.003）、抗CENPB（P = 0.034）、抗CENPA（P = 0.034）和抗Scl-70（P < 0.001）的患病率增加。此外，伴间质性肺疾病（ILD）的SSc患者抗Ro-52（P = 0.046）和抗Scl-70（P = 0.035）的患病率增加，而抗CENPB（P < 0.001）和抗CENPA（P < 0.001）的患病率降低。此外，伴有肺动脉高压（PAH）的SSc患者抗Ro-52的患病率增加（P = 0.013），抗Scl-70的患病率降低（P = 0.001）。抗Ro-52和抗Scl-70对SSc患者ILD的预测价值较高，而抗Ro-52对SSc患者PAH的预测价值较高。结论：商品化的自身抗体免疫分析法可用于评估中国汉族SSc患者自身抗体的诊断价值。结果清楚地表明，免疫印迹试验具有良好的诊断实用性SSc。抗Ro-52、抗RP 11、抗CENPB、抗CENPA和抗Sc 1 -70对中国汉族人群SSc的诊断有一定的临床意义。抗Ro-52、抗CENPB、抗CENPA和抗Scl-70对SSc患者ILD的诊断有潜在价值。此外，抗Ro-52和抗Sc 1 -70可用于诊断SSc患者的PAH。
Objective: The autoantibody profile, which varies between races, has rarely been reported in Chinese Han systemic sclerosis (SSc) patients. The present study aims to investigate the autoantibody profile of Chinese Han SSc patients using a commercial line immunoassay.Methods: The prevalence of autoantibodies to Ro-52, PDGFR, Ku, PM75, PM100, Th/To, NOR90, Fib, RP155, RP11, CENP-B, CENP-A and Scl-70 were analyzed in serum samples obtained from healthy controls (n = 30), SSc patients (n = 320) and non-SSc connective-tissue disease patients (n = 100) using an Euroline Systemic Sclerosis Profile kit.Results: SSc patients had increased prevalence of anti-RP11 (P = 0.032), anti-CENPB (P < 0.001), anti-CENPA (P = 0.001) and anti-Scl-70 (P < 0.001), but had decreased prevalence of anti-Ro-52 (P = 0.004), when compared to non-SSc CTDs. Furthermore, SSc patients had increased prevalence of anti-Ro-52 (P = 0.003), anti-CENPB (P = 0.034), anti-CENPA (P = 0.034) and anti-Scl-70 (P < 0.001), when compared to HCs. In addition, SSc patients with interstitial lung disease (ILD) had increased prevalence of anti-Ro-52 (P = 0.046) and anti-Scl-70 (P = 0.035), but had decreased prevalence of anti-CENPB (P < 0.001) and anti-CENPA (P < 0.001). Moreover, SSc patients with pulmonary arterial hypertension (PAH) had increased prevalence of anti-Ro-52 (P = 0.013) and decreased prevalence of anti-Scl-70 (P = 0.001). Anti-Ro-52 and anti-Scl-70 had increased values for predicting ILD in SSc patients, while anti-Ro-52 had increased values for predicting PAH in SSc patients.Conclusion: A commercial line immunoassay was used to evaluate the diagnostic value of autoantibodies in Chinese Han SSc patients. The results clearly indicate that the immunoblot assay has good diagnostic utility for SSc. Anti-Ro-52, anti-RP11, anti-CENPB, anti-CENPA and anti-Sc1-70 are useful for diagnosing SSc in the Chinese Han population. Anti-Ro-52, anti-CENPB, anti-CENPA and anti-Scl-70 have a potential value for diagnosing ILD in SSc patients. Furthermore, anti-Ro-52 and anti-Sc1-70 may be used to diagnose PAH in SSc patients.